Treatment of hair loss disorders with deuterated JAK inhibitors
Disclosed is a method of treating in a subject hair loss disorders that are beneficially treated by administering a JAK1 and/or JAK2 inhibitor. The method comprises administering to the subject an amount in the range of about 4 mg to about 50 mg of Compound (I): or a pharmaceutically acceptable salt thereof. This invention also provides compositions comprising Compound (I) and the use of such compositions in the described methods.
1. A method of treating a hair loss disorder in a human subject, the method comprising administering to the human subject 16 mg/day of a compound represented by the following structural formula:
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
2. The method of claim 1 , wherein the hair loss disorder is alopecia areata.
3. The method of claim 1 , wherein the compound is administered orally.
4. The method of claim 1 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.
5. The method of claim 1 , wherein the compound is administered once a day.
6. The method of claim 1 , wherein the compound is administered twice a day.
7. The method of claim 6 , wherein the step of administering comprises administering to the subject 8 mg of the compound twice per day.
8. The method of claim 1 , wherein the incorporation of deuterium at each position designated specifically as deuterium is at least 97%.
9. The method of claim 1 , wherein the compound is orally administered as a phosphate salt.
10. The method of claim 9 , wherein the phosphate salt is administered once a day.
11. The method of claim 9 , wherein the phosphate salt is administered twice a day.
12. The method of claim 8 , wherein the compound is orally administered as a phosphate salt.
13. The method of claim 12 , wherein the phosphate salt is administered once a day.
14. The method of claim 12 , wherein the phosphate salt is administered twice a day.
15. The method of claim 2 , wherein the compound is administered orally.
16. The method of claim 2 , wherein the compound is administered in a pharmaceutical formulation which is a tablet.
17. The method of claim 2 , wherein the compound is administered once a day.
18. The method of claim 2 , wherein the compound is administered twice a day.
19. The method of claim 18 , wherein the step of administering comprises administering to the subject 8 mg of the compound twice per day.
20. The method of claim 2 , wherein the incorporation of deuterium at each position designated specifically as deuterium is at least 97%.
21. The method of claim 2 , wherein the compound is orally administered as a phosphate salt.
22. The method of claim 21 , wherein the phosphate salt is administered once a day.
23. The method of claim 21 , wherein the phosphate salt is administered twice a day.
24. The method of claim 20 , wherein the compound is orally administered as a phosphate salt.
25. The method of claim 24 , wherein the phosphate salt is administered once a day.
26. The method of claim 24 , wherein the phosphate salt is administered twice a day.
27. A method of treating alopecia areata in a human subject, the method comprising orally administering to the human subject 8 mg twice per day of a compound represented by the following structural formula:
wherein Compound (I) is administered as a phosphate salt, and
wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.
28. The method of claim 27 , wherein the incorporation of deuterium at each position designated specifically as deuterium is at least 97%.
29. The method of claim 28 , wherein the Compound (I) is administered in a tablet.